Antitumor efficacy of (90)Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors

BACKGROUND: Systemic radiation treatments that preferentially irradiate cancer cells over normal tissue, known as targeted radionuclide therapy (TRT), have shown significant potential for treating metastatic prostate cancer. Preclinical studies have demonstrated the ability of external beam radiatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Potluri, Hemanth K, Ferreira, Carolina A, Grudzinski, Joseph, Massey, Christopher, Aluicio-Sarduy, Eduardo, Engle, Jonathan W, Kwon, Ohyun, Marsh, Ian R, Bednarz, Bryan P, Hernandez, Reinier, Weichert, Jamey P, McNeel, Douglas G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413196/
https://www.ncbi.nlm.nih.gov/pubmed/36002185
http://dx.doi.org/10.1136/jitc-2022-005060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413196/
https://www.ncbi.nlm.nih.gov/pubmed/36002185
http://dx.doi.org/10.1136/jitc-2022-005060

Ejemplares similares